Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Free Cash Flow: 2014-2025

Historic Free Cash Flow for KalVista Pharmaceuticals (KALV) over the last 8 years, with Apr 2025 value amounting to -$40.6 million.

  • KalVista Pharmaceuticals' Free Cash Flow fell 166.88% to -$40.6 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$135.8 million, marking a year-over-year decrease of 51.54%. This contributed to the annual value of -$153.4 million for FY2025, which is 71.15% down from last year.
  • According to the latest figures from Q2 2025, KalVista Pharmaceuticals' Free Cash Flow is -$40.6 million, which was down 2.17% from -$39.7 million recorded in Q4 2024.
  • KalVista Pharmaceuticals' 5-year Free Cash Flow high stood at -$15.2 million for Q2 2024, and its period low was -$40.6 million during Q2 2025.
  • In the last 3 years, KalVista Pharmaceuticals' Free Cash Flow had a median value of -$27.7 million in 2024 and averaged -$30.0 million.
  • Data for KalVista Pharmaceuticals' Free Cash Flow shows a maximum YoY crashed of 166.88% (in 2025) over the last 5 years.
  • Over the past 3 years, KalVista Pharmaceuticals' Free Cash Flow (Quarterly) stood at -$20.0 million in 2023, then crashed by 98.46% to -$39.7 million in 2024, then tumbled by 166.88% to -$40.6 million in 2025.
  • Its Free Cash Flow stands at -$40.6 million for Q2 2025, versus -$39.7 million for Q4 2024 and -$40.3 million for Q3 2024.